喹扎替尼与颅脑脊髓照射联合治疗对伴有中枢神经系统受累的FMS样酪氨酸激酶3-内部串联重复阳性难治性急性髓系白血病的临床意义。
Clinical implications of combination therapy with quizartinib and craniospinal irradiation for refractory acute myeloid leukemia positive for FMS-like tyrosine kinase 3-internal tandem duplication with central nervous system involvement.
作者信息
Suga Makiko, Fukushima Kentaro, Ueda Tomoaki, Arai Yasuyuki, Nakagawa Shunsaku, Minami Yosuke, Toda Jun, Hino Akihisa, Fujita Jiro, Yokota Takafumi, Hosen Naoki
机构信息
Department of Hematology and Oncology Osaka University Graduate School of Medicine Suita Japan.
Department of Hematology and Oncology Kyoto University Hospital Kyoto Japan.
出版信息
Clin Case Rep. 2022 Feb 4;10(2):e05384. doi: 10.1002/ccr3.5384. eCollection 2022 Feb.
Abstract
FMS-like tyrosine kinase 3-internal tandem duplication (-ITD) mutation-positive acute myeloid leukemia (AML) has a poor prognosis. We report the first case of successful bridge therapy of novel FLT3 inhibitor, quizartinib, to umbilical cord blood stem cell transplantation for -ITD-positive AML-primary induction failure patients with central nervous system involvement.
摘要
FMS样酪氨酸激酶3内部串联重复（-ITD）突变阳性的急性髓系白血病（AML）预后较差。我们报告了首例针对-ITD阳性AML伴中枢神经系统受累且初次诱导失败的患者，成功将新型FLT3抑制剂奎扎替尼用于桥接治疗至脐带血干细胞移植的病例。
相似文献
1
Clinical implications of combination therapy with quizartinib and craniospinal irradiation for refractory acute myeloid leukemia positive for FMS-like tyrosine kinase 3-internal tandem duplication with central nervous system involvement.
Clin Case Rep. 2022 Feb 4;10(2):e05384. doi: 10.1002/ccr3.5384. eCollection 2022 Feb.
2
Quizartinib, an FLT3 inhibitor, as monotherapy in patients with relapsed or refractory acute myeloid leukaemia: an open-label, multicentre, single-arm, phase 2 trial.
Lancet Oncol. 2018 Jul;19(7):889-903. doi: 10.1016/S1470-2045(18)30240-7. Epub 2018 May 31.
3
Quizartinib plus chemotherapy in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia (QuANTUM-First): a randomised, double-blind, placebo-controlled, phase 3 trial.
Lancet. 2023 May 13;401(10388):1571-1583. doi: 10.1016/S0140-6736(23)00464-6. Epub 2023 Apr 25.
4
Improved efficacy of quizartinib in combination therapy with PI3K inhibition in primary FLT3-ITD AML cells.
Adv Biol Regul. 2023 Aug;89:100974. doi: 10.1016/j.jbior.2023.100974. Epub 2023 May 23.
5
Phase I study of quizartinib administered daily to patients with relapsed or refractory acute myeloid leukemia irrespective of FMS-like tyrosine kinase 3-internal tandem duplication status.
J Clin Oncol. 2013 Oct 10;31(29):3681-7. doi: 10.1200/JCO.2013.48.8783. Epub 2013 Sep 3.
6
Clinical Outcomes in Patients with FLT3-ITD-Mutated Relapsed/Refractory Acute Myelogenous Leukemia Undergoing Hematopoietic Stem Cell Transplantation after Quizartinib or Salvage Chemotherapy in the QuANTUM-R Trial.
Transplant Cell Ther. 2021 Feb;27(2):153-162. doi: 10.1016/j.bbmt.2020.09.036. Epub 2020 Oct 2.
7
Outcome of FLT3-ITD-positive acute myeloid leukemia: impact of allogeneic stem cell transplantation and tyrosine kinase inhibitor treatment.
J Cancer Res Clin Oncol. 2017 Feb;143(2):337-345. doi: 10.1007/s00432-016-2290-5. Epub 2016 Oct 24.
8
Quizartinib versus salvage chemotherapy in relapsed or refractory FLT3-ITD acute myeloid leukaemia (QuANTUM-R): a multicentre, randomised, controlled, open-label, phase 3 trial.
Lancet Oncol. 2019 Jul;20(7):984-997. doi: 10.1016/S1470-2045(19)30150-0. Epub 2019 Jun 4.
9
Efficacy and safety of quizartinib in Japanese patients with FLT3-ITD positive relapsed or refractory acute myeloid leukemia in an open-label, phase 2 study.
Int J Hematol. 2019 Dec;110(6):665-674. doi: 10.1007/s12185-019-02727-6. Epub 2019 Aug 31.
10
Homoharringtonine synergizes with quizartinib in FLT3-ITD acute myeloid leukemia by targeting FLT3-AKT-c-Myc pathway.
Biochem Pharmacol. 2021 Jun;188:114538. doi: 10.1016/j.bcp.2021.114538. Epub 2021 Apr 6.
引用本文的文献
1
Therapeutics of acute myeloid leukemia with central nervous system involvement.
Clin Hematol Int. 2025 Mar 11;7(1):40-46. doi: 10.46989/001c.131722. eCollection 2025.
本文引用的文献
1
A Relapsing Meningeal Acute Myeloid Leukaemia FLT3-ITD+ Responding to Gilteritinib.
Chemotherapy. 2021;66(4):134-138. doi: 10.1159/000518356. Epub 2021 Aug 24.
2
Clinical Outcomes in Patients with FLT3-ITD-Mutated Relapsed/Refractory Acute Myelogenous Leukemia Undergoing Hematopoietic Stem Cell Transplantation after Quizartinib or Salvage Chemotherapy in the QuANTUM-R Trial.
Transplant Cell Ther. 2021 Feb;27(2):153-162. doi: 10.1016/j.bbmt.2020.09.036. Epub 2020 Oct 2.
3
Which are the most promising targets for minimal residual disease-directed therapy in acute myeloid leukemia prior to allogeneic stem cell transplant?
Haematologica. 2019 Aug;104(8):1521-1531. doi: 10.3324/haematol.2018.208587.
4
Safety and pharmacokinetics of quizartinib in Japanese patients with relapsed or refractory acute myeloid leukemia in a phase 1 study.
Int J Hematol. 2019 Dec;110(6):654-664. doi: 10.1007/s12185-019-02709-8. Epub 2019 Jul 29.
5
Availability of FLT3 inhibitors: how do we use them?
Blood. 2019 Aug 29;134(9):741-745. doi: 10.1182/blood.2019876821. Epub 2019 Jun 26.
6
Quizartinib versus salvage chemotherapy in relapsed or refractory FLT3-ITD acute myeloid leukaemia (QuANTUM-R): a multicentre, randomised, controlled, open-label, phase 3 trial.
Lancet Oncol. 2019 Jul;20(7):984-997. doi: 10.1016/S1470-2045(19)30150-0. Epub 2019 Jun 4.
7
Effects of CYP3A inhibitors on the pharmacokinetics of quizartinib, a potent and selective FLT3 inhibitor, and its active metabolite.
Br J Clin Pharmacol. 2019 Sep;85(9):2108-2117. doi: 10.1111/bcp.14022. Epub 2019 Jul 23.
8
Precision medicine and novel molecular target therapies in acute myeloid leukemia: the background of hematologic malignancies (HM)-SCREEN-Japan 01.
Int J Clin Oncol. 2019 Aug;24(8):893-898. doi: 10.1007/s10147-019-01467-1. Epub 2019 May 20.
9
Venetoclax penetrates in cerebrospinal fluid and may be effective in chronic lymphocytic leukemia with central nervous system involvement.
Haematologica. 2019 May;104(5):e222-e223. doi: 10.3324/haematol.2018.213157. Epub 2019 Feb 14.
10
Phase 2b study of 2 dosing regimens of quizartinib monotherapy in -ITD-mutated, relapsed or refractory AML.
Blood. 2018 Aug 9;132(6):598-607. doi: 10.1182/blood-2018-01-821629. Epub 2018 Jun 6.
Zotero 插件